SBIR: Antibody-based approaches for pre- and post-exposure prophylaxis and/or treatment for influenza, coronaviruses, and measles
Forecast New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $7,000,000 to $13,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is forecasting a new Total Small Business SBIR requirement for milestone-driven pre-clinical development of antibody-based drug candidates for pre- and post-exposure prophylaxis and treatment of influenza, coronaviruses, or measles, with an estimated solicitation release date of May 1, 2027. Strategies should aim to reduce the severity, duration, and transmission of infection in at-risk populations and may include nanobodies, aptamers, or similar technologies. Scope ranges from product candidate discovery (Phase I only) or optimization to preclinical process development leading to IND filing (Phase I or II), with Fast-Track and Direct-to-Phase II proposals accepted.
NIH anticipates 3-4 awards with an estimated award date of October 1, 2027, and an estimated award value range of $7 million to $13 million. Total costs are up to $700,000 for up to 2 years for Phase I and up to $2,000,000 for up to 3 years for Phase II. Points of contact are Callie Prassinos, Contracting Officer (callie.prassinos@nih.gov, +1 (240) 669-5155), and Dipanwita Basu, Program Officer for Influenza, Coronavirus Therapeutics, Diagnostics (dipanwita.basu@nih.gov).
Forecast text
The goal of this solicitation is to support milestone-driven programs for the pre-clinical development of antibody-based drug candidates for use as pre- and post-exposure prophylaxis and treatment of Influenza, Coronaviruses or Measles. The strategies should aim to reduce the severity, duration, and transmission of infection in at-risk populations. Antibody-based strategies may include nanobodies, aptamers, or similar technologies. The scope of the proposed activities can range from product candidate discovery (Phase I only) or optimization to preclinical process development leading to IND filing (Phase I or II). Offerors may propose to establish initial proof-of-concept data in cells or animals, conduct preclinical process development, or production of antibody-based drug candidates.
Fast-Track proposals will be accepted.
Direct-to-Phase II proposals will be accepted.
Number of anticipated awards: 3-4
Budget (total costs):
Phase I: Up to $700,000 for up to 2 years
Phase II: Up to $2,000,000 for up to 3 years
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast